TherapeuticsMD Inc (TXMD) - Total Assets
Based on the latest financial reports, TherapeuticsMD Inc (TXMD) holds total assets worth $37.66 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TherapeuticsMD Inc - Total Assets Trend (1994–2025)
This chart illustrates how TherapeuticsMD Inc's total assets have evolved over time, based on quarterly financial data. Also see TherapeuticsMD Inc stock valuation for the company's overall valuation and market capitalisation.
TherapeuticsMD Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
TherapeuticsMD Inc's total assets of $37.66 Million consist of 38.4% current assets and 61.6% non-current assets. Review TherapeuticsMD Inc (TXMD) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.9% |
| Accounts Receivable | $3.52 Million | 9.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.76 Million | 10.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1994–2025)
This chart illustrates how TherapeuticsMD Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for TherapeuticsMD Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TherapeuticsMD Inc's current assets represent 38.4% of total assets in 2025, an increase from 20.0% in 1994.
- Cash Position: Cash and equivalents constituted 19.9% of total assets in 2025, up from 4.5% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 10.0% of total assets.
TherapeuticsMD Inc Competitors by Total Assets
Key competitors of TherapeuticsMD Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
Turkey | TL70.69 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥10.50 Billion |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
China | CN¥2.33 Billion |
TherapeuticsMD Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.02 | 1.92 | 3.05 |
| Quick Ratio | 3.02 | 1.92 | 2.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.66 Million | $4.76 Million | $125.76 Million |
TherapeuticsMD Inc - Advanced Valuation Insights
This section examines the relationship between TherapeuticsMD Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.87 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | $37.66 Million |
| Market Capitalization | $22.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values TherapeuticsMD Inc's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: TherapeuticsMD Inc's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for TherapeuticsMD Inc (1994–2025)
The table below shows the annual total assets of TherapeuticsMD Inc from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $37.66 Million | -3.00% |
| 2024-12-31 | $38.82 Million | -10.36% |
| 2023-12-31 | $43.31 Million | -52.12% |
| 2022-12-31 | $90.46 Million | -46.62% |
| 2021-12-31 | $169.47 Million | -6.68% |
| 2020-12-31 | $181.61 Million | -31.72% |
| 2019-12-31 | $265.99 Million | +25.47% |
| 2018-12-31 | $211.98 Million | +48.00% |
| 2017-12-31 | $143.23 Million | +0.53% |
| 2016-12-31 | $142.47 Million | +93.24% |
| 2015-12-31 | $73.73 Million | +24.80% |
| 2014-12-31 | $59.08 Million | -4.74% |
| 2013-12-31 | $62.02 Million | +965.92% |
| 2012-12-31 | $5.82 Million | +304.39% |
| 2011-12-31 | $1.44 Million | +207.80% |
| 2010-12-31 | $467.42K | -44.99% |
| 2009-12-31 | $849.76K | +1461.52% |
| 2008-12-31 | $54.42K | -89.01% |
| 2007-12-31 | $495.36K | -73.47% |
| 2006-12-31 | $1.87 Million | +3.30% |
| 2005-12-31 | $1.81 Million | +66.05% |
| 2004-12-31 | $1.09 Million | +21.19% |
| 2003-12-31 | $898.22K | +19.25% |
| 2002-12-31 | $753.21K | +8.36% |
| 2001-12-31 | $695.12K | +10.66% |
| 2000-12-31 | $628.17K | +26.10% |
| 1999-12-31 | $498.16K | -2.10% |
| 1998-12-31 | $508.85K | +0.79% |
| 1997-12-31 | $504.88K | -2.10% |
| 1996-12-31 | $515.70K | +2.12% |
| 1995-12-31 | $505.02K | +17.36% |
| 1994-12-31 | $430.33K | -- |
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vag… Read more